Status:
TERMINATED
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
Lead Sponsor:
Henry Ford Health System
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Head and Neck Cancer
Carcinoma, Squamous Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine if combination Erlotinib, Cisplatin/Carboplatin, and Paclitaxel are effective first line treatment for metastatic, recurrent and persistent squamous cell carc...
Detailed Description
We hypothesize that Erlotinib fails to enhance the effects of chemotherapy on response and survival because of Erlotinib's cytostatic effect, this results in a slowing down of the cell cycle, this in ...
Eligibility Criteria
Inclusion
- Squamous cell carcinoma of the head and neck region that is metastatic, recurrent or persistent after surgery and/or radiation
- No prior chemotherapy for metastatic, recurrent or persistent disease
Exclusion
- Not more than 1 prior adjuvant or neoadjuvant chemotherapy regimen is allowed
- Chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00448240
Start Date
February 1 2007
End Date
January 1 2012
Last Update
March 18 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.